Remedium Lifecare Posts Strong Q2 And H1 Growth Momentum
ECONOMY & POLICY

Remedium Lifecare Posts Strong Q2 And H1 Growth Momentum

Remedium Lifecare Limited has announced its consolidated financial results for the quarter and half-year ended 30 September 2025, reporting strong operational momentum and continued progress in business expansion.

For Q2 FY26, consolidated revenue from operations stood at Rs 1.11 billion, while total income reached Rs 1.14 billion. The company reported consolidated profit before tax of Rs 104.37 million and profit after tax of Rs 38.62 million. Earnings per share were Rs 0.10, doubling from Q1 FY26.

For the half-year period, consolidated revenue from operations totalled Rs 2.24 billion, with total income at Rs 2.31 billion. Profit before tax for H1 FY26 was Rs 316.49 million, and profit after tax reached Rs 132.72 million, translating to earnings per share of Rs 0.15. Consolidated total assets stood at Rs 16.23 billion as of 30 September 2025.

Commenting on the results, Mr Adarsh Munjal, Whole-Time Director, said the second-quarter performance reflected the company’s ongoing commitment to operational discipline and strategic expansion. He noted that the consolidated results demonstrate the strength of the company’s portfolio and its ability to scale efficiently. He added that the company expects momentum to continue through the remainder of the financial year as it focuses on profitability, asset strengthening, and sustainable growth.

Remedium Lifecare has recently strengthened its leadership with the appointment of Mr Rambhajan Vishwakarma and Mr Vignesh Laxman Gawde to the Board, signalling enhanced focus on governance, global expansion, and scaling of CDMO capabilities.

The company’s broader strategy—leveraging its global-subsidiary network, including a Singapore entity incorporated in September 2024, and expanding its CDMO service offerings—reinforces its ambition to strengthen and monetise its specialty pharmaceuticals and chemicals business

Remedium Lifecare Limited has announced its consolidated financial results for the quarter and half-year ended 30 September 2025, reporting strong operational momentum and continued progress in business expansion. For Q2 FY26, consolidated revenue from operations stood at Rs 1.11 billion, while total income reached Rs 1.14 billion. The company reported consolidated profit before tax of Rs 104.37 million and profit after tax of Rs 38.62 million. Earnings per share were Rs 0.10, doubling from Q1 FY26. For the half-year period, consolidated revenue from operations totalled Rs 2.24 billion, with total income at Rs 2.31 billion. Profit before tax for H1 FY26 was Rs 316.49 million, and profit after tax reached Rs 132.72 million, translating to earnings per share of Rs 0.15. Consolidated total assets stood at Rs 16.23 billion as of 30 September 2025. Commenting on the results, Mr Adarsh Munjal, Whole-Time Director, said the second-quarter performance reflected the company’s ongoing commitment to operational discipline and strategic expansion. He noted that the consolidated results demonstrate the strength of the company’s portfolio and its ability to scale efficiently. He added that the company expects momentum to continue through the remainder of the financial year as it focuses on profitability, asset strengthening, and sustainable growth. Remedium Lifecare has recently strengthened its leadership with the appointment of Mr Rambhajan Vishwakarma and Mr Vignesh Laxman Gawde to the Board, signalling enhanced focus on governance, global expansion, and scaling of CDMO capabilities. The company’s broader strategy—leveraging its global-subsidiary network, including a Singapore entity incorporated in September 2024, and expanding its CDMO service offerings—reinforces its ambition to strengthen and monetise its specialty pharmaceuticals and chemicals business

Next Story
Infrastructure Urban

Jyoti Structures FY26 profit rises 56.5%

Jyoti Structures (JSL) recently reported strong financial results for the quarter and year ended 31 March 2026, driven by disciplined execution, cost management and steady progress across its order book.For Q4 FY2025-26, total income rose 44.2 per cent to Rs 2.41 billion from Rs 1.67 billion in Q4 FY2024-25. EBITDA increased 58.6 per cent to Rs 237 million, while EBITDA margin improved by 89 basis points to 9.84 per cent. Profit before tax grew 53.3 per cent to Rs 188.5 million, and net profit rose 51.9 per cent to Rs 181.4 million.For FY2025-26, total income grew 53.1 per cent to Rs 7.72 bill..

Next Story
Infrastructure Energy

Cat BEPU to Power Doppstadt Separator at IFAT 2026

Caterpillar’s Cat Battery Electric Power Unit (BEPU) has been selected by Doppstadt to power its SWS 6 Spiral Shaft Separator, which will be showcased for the first time at IFAT 2026 in Munich, Germany, from 4–7 May.The compact plug-and-play BEPU is designed to replace a diesel engine within the same space, using the same mounting locations and relative machine position. It integrates the battery, motor, inverter, onboard charging, cooling and controls, enabling OEMs to electrify existing chassis platforms without extensive redesign.Caterpillar and Cat dealer Zeppelin Power Systems have be..

Next Story
Infrastructure Urban

VECV sales rise 6.9% in April 2026

VE Commercial Vehicles, a joint venture between Volvo Group and Eicher Motors, recorded sales of 7,318 units in April 2026, compared to 6,846 units in April 2025, registering 6.9 per cent growth. The total included 7,159 units under the Eicher brand and 159 units under the Volvo brand.Eicher branded trucks and buses reported sales of 7,159 units during the month, up 6.6 per cent from 6,717 units in April 2025. In the domestic commercial vehicle market, Eicher sales rose 8.6 per cent to 6,797 units from 6,257 units a year earlier.Exports declined 21.3 per cent, with VECV recording 362 units in ..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement